ulobetasol

ウロベタゾール

関

halobetasol

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/11/02 16:32:54」(JST)

wiki en

[Wiki en表示]

Ulobetasol

Systematic (IUPAC) name
(6α,11β,16β)-21-chloro-6,9-difluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a601060
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	98651-66-2 N
ATC code	D07AC21
PubChem	CID 5311167
ChemSpider	4470691 Y
UNII	9P6159HM7T Y
KEGG	D08660 Y
ChEMBL	CHEMBL1201360 N
Synonyms	(6S,8S,9S,10S,11S,13S,14S,16S,17R)-17-(2-Chloroacetyl)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
Chemical data
Formula	C22H27ClF2O4
Mol. mass	428.897
SMILES ClCC(=O)[C@]3(O)[C@]2(C[C@H](O)[C@]4(F)[C@@]/1(\C(=C/C(=O)\C=C\1)[C@@H](F)C[C@H]4[C@@H]2C[C@@H]3C)C)C
InChI InChI=1S/C22H27ClF2O4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1 Y Key:LEHFPXVYPMWYQD-XHIJKXOTSA-N Y
N (what is this?)  (verify)

Ulobetasol (or halobetasol) is a corticosteroid used to treat psoriasis. It is a group I corticosteroid under the US classification, the most potent class of such drugs. Halobetasol propionate is usually supplied as a 0.05% topical cream.

External links

• halobetasol at the US National Library of Medicine Medical Subject Headings (MeSH)

English Journal

• Impurity profiling and a stability-indicating UPLC method development and validation for the estimation of related impurities of halobetasol propionate in halobetasol propionate 0.05% (w/w) cream.

• Prakash L1, Malipeddi H2, Subbaiah BV3, Lakka NS3.
• Journal of chromatographic science.J Chromatogr Sci.2015 Jan;53(1):112-21. doi: 10.1093/chromsci/bmu027. Epub 2014 May 2.
• A simple, short and stability-indicating reverse phase-ultra-performance liquid chromatography method was developed and validated for the quantitative determination of related impurities of halobetasol propionate in halobetasol propionate 0.05% cream formulation. The proposed method was developed on
• PMID 24795078

• Quantification of halobetasol propionate and its impurities present in topical dosage forms by stability-indicating LC method.

• Nalwade S1, Reddy VR2, Kulkarni D3, Todamal S3.
• Journal of chromatographic science.J Chromatogr Sci.2015 Jan;53(1):127-34. doi: 10.1093/chromsci/bmu029. Epub 2014 Apr 30.
• A novel, sensitive, stability-indicating, gradient, reverse-phase high-performance liquid chromatographic method has been developed for quantitative determination of halobetasol propionate and its impurities in topical dosage forms. The chromatographic separation was achieved on a Phenomenex Synergi
• PMID 24784115

• An investigator-initiated, double-blind, vehicle-controlled pilot study: assessment for tachyphylaxis to topically occluded halobetasol 0.05% ointment in the treatment of psoriasis.

• Czarnowicki T1, Linkner RV2, Suárez-Fariñas M3, Ingber A4, Lebwohl M2.
• Journal of the American Academy of Dermatology.J Am Acad Dermatol.2014 Nov;71(5):954-959.e1. doi: 10.1016/j.jaad.2014.05.040. Epub 2014 Jun 11.
• BACKGROUND: Topical corticosteroids are the most common first-line treatment for psoriasis. Tachyphylaxis, a decreased response to treatment with repetitive application of the drug, is a controversial phenomenon associated with topical corticosteroid treatment.OBJECTIVE: We sought to prove or dispro
• PMID 24929883

---

★リンクテーブル★

リンク元	「ウロベタゾール」「halobetasol」

「ウロベタゾール」

　　[★]

英

ulobetasol

関

ハロベタソール

「halobetasol」

　　[★]

ハロベタソール

関

ulobetasol